

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC
Form 8-K
December 09, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 3, 2004

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23143	13-3379479
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York	10591
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Section 7 - Regulation FD

Item 7.01 Regulation FD Disclosure

Progenics Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the first of two pivotal phase 3 clinical trials of its investigational drug, methylnaltrexone (MNTX) for the treatment of opioid-induced constipation in patients with advanced medical illness (AMI). The Company expects to announce top-line results from the 150-patient, multi-center, double-blind, randomized, placebo-controlled phase 3 study in early 2005.

The information furnished pursuant to Item 7.01 in this Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that Section, unless we specifically incorporate it by reference in a document filed under the

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no duty or obligation to publicly update or revise the information furnished pursuant to Item 7.01 in this Form 8-K.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statement and Exhibits

(c) the following exhibits are filed with this report

Exhibit Number	Description
99.1	Press release dated December 3, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ROBERT A. MCKINNEY

Robert A. McKinney
Vice President, Finance & Operations

Date: December 8, 2004